Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates

Ultragenyx Pharmaceutical (RARE) incurred a third-quarter 2024 loss of $1.40 per share, narrower than the Zacks Consensus Estimate of a loss of$1.45. The company had reported a loss of $2.23 per share in the year-ago quarter.      Ultragenyx’s total revenues amounted to$139.5 million in the reported quarter, up 42% year over year. The top line surpassed the Zacks Consensus Estimate of $134 million on the back of higher product revenues.The company markets four drugs, namely Crysvita, Mepsevii, Dojolvi and ...